A Phase 4 interventional study of Dapagliflozin 10mg Tab in Breast Cancer, sponsored by Helwan University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Helwan University · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Breast Neoplasms with a site in Egypt — 58 open to participants now, 68 under way, 5 of them phase 3. Breast Neoplasms · Egypt.
Among the 248 studies in Breast Neoplasms with a site in Egypt, this one is the 156th largest by planned enrollment of the 183 interventional ones that give a count, is one of 31 that started in 2024, is one of 11 in phase 4, reaches primary completion later than 24 of the 67 other live ones, and was the 176th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →58 of the 248 studies in Breast Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 65–75 · Women only
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–65 · Women only
Adly A Adam · Sites in Egypt
Ages 40–50 · Women only
Sohag University · Sites in Egypt
Ages 18–80
Alexandria University · Sites in Egypt
Ages 18–70 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 46 · Phase 3 47 · Phase 4 11
First in 1997; this study’s year is marked. 31 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 70 across the 183 interventional studies, 100 across the 63 observational. Of the 131 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 248 have an industry lead sponsor. The 10 most frequent:
Helwan University is the lead sponsor of 70 studies on the registry; 15 are open to participants now.
Helwan University has 3 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Breast Neoplasms with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596122Abdelrahman MahmoudVitamin D Supplementation in Breast Cancer Patients | 2026-11-30 |
| NCT07095569National Cancer Institute, EgyptShoulder Denervation for Post Mastectomy Irradiation Shoulder Pain | 2026-12-01 |
| NCT07650305National Cancer Institute, EgyptBilevel Erector Spinae Plane Block Versus Pectoserratus Block for Analgesia in Modified Radical Mastectomy | 2026-12-01 |
| NCT07894133Adly A AdamGait Parameters in Breast Cancer Receiving Chemotherapy Patients | 2026-12-01 |
| NCT01101425European Organisation for Research and Treatment of Cancer - EORTCMale Breast Cancer: Understanding the Biology for Improved Patient Care | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 248 studies in Breast Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug.
Aim of the study:
Evaluate cardioprotective effect and safety of dapagliflozin against anthracyclines-induced cardiotoxicity.
The main questions it aims to answer are:
Treatment
Breast cancer is a malignant tumor that originates in the cells of the breast tissue. It is the most common cancer in women worldwide, accounting for 24.2% of all cancer cases among women.
According to the latest World Health Organization statistics, there were an estimated 2.3 million new cases of breast cancer in 2020; it is the second leading cause of cancer death in women after lung cancer.
In Egypt, breast cancer is the most common malignancy in women, accounting for 38.8% of cancers in this population, with the estimated number of breast cancer cases nearly 22,700 in 2022 and forecasted to be approximately 46,000 in 2050.
Anthracyclines are well-established and highly effective anti-neoplastic agents, used to treat several adult and pediatric cancers, such as breast cancer, leukemia, lymphomas, sarcomas, and many others.
Anthracycline-induced cardiotoxicity typically manifests as a reduction in left ventricular ejection fraction (LVEF), cardiomyopathy, or symptomatic congestive heart failure (CHF).
Acute anthracycline cardiotoxicity - occurs during or immediately after a single dose of an anthracycline. It may manifest as ventricular dysfunction, ECG abnormalities and arrhythmias.
Cardiotoxicity as a result of anthracycline chemotherapy has been linked to increased morbidity and mortality in breast cancer patients.
In a recently published cohort study, 2000 cancer survivors were monitored over 7 years. The authors found that approximately one-third of deaths could be attributed to long-term cardiotoxicity.
The specific mechanisms of anthracycline cardiotoxicity by Oxidative stress, which in the presence of iron, generates reactive oxygen species that cause lipid peroxidation of the cell membrane leading to damage of the cardiomyocytes, inflammation by up-regulating the levels of various inflammatory mediators, including interleukin-1 and tumor necrosis factor-α in the heart, subsequently leading to cardiomyocyte damage, In addition, DOX activated the nod-like receptor pyrin domain containing 3 (NLRP3) in cardiomyocytes, promoting cardiomyocyte apoptosis and down-regulation of sirtuin and adenosine monophosphate-activated protein kinase (AMPK) activity which associated with cardiovascular disease by enhanced apoptosis and increased fibrosis. The cardiomyocyte has always been considered the main cellular target of anthracycline toxic effect in the heart, as their destruction results in the progressive development of cardiac dysfunction.
Since anthracyclines is known to cause cardiotoxicity as a side effect, a baseline echocardiogram (ECHO) is ordered for each patient before initiating anthracycline chemotherapy treatment as a standard of care. Additionally, follow-up ECHOs are conducted after starting the treatment cycles to detect any early signs of cardiotoxicity.
Sodium Glucose co-transport inhibitors (SGLT2i) have demonstrated significant cardioprotective effects beyond their glucose-lowering capabilities. Recent clinical studies have highlighted their ability to reduce cardiovascular events, such as heart failure and myocardial infarction, in diabetic patients.
The cardioprotective benefits are thought to arise from multiple mechanisms, including improved cardiac energy metabolism, reduced blood pressure, and decreased fluid overload. As a result, SGLT2i are emerging as a crucial therapeutic option not only for glycemic control but also for enhancing heart health, marking a promising advancement in the management of cardiovascular risks.
SGLT2i significantly reduces Systolic Blood Pressure (SBP) and arterial stiffness that leads to better oxygen consumption by myocardium and hence lowers the cardiac afterload. It also helps in reducing the body weight slightly. Additionally, dapagliflozin also contributes by lowering the plasma volume by diuresis i.e., the increased excretion of sodium and glucose in urine. Decreasing the inflammation pathway by modulating the activation of NLRP3 inflammasome, thereby attenuating the synthesis of proinflammatory cytokines and reduced levels of tumor necrosis factor-α and interleukins, decreasing oxidative Stress by attenuate the generation of reactive oxygen species and enhance antioxidant mechanisms by inhibiting NADPH oxidase (nicotinamide adenine dinucleotide phosphate hydrogen ) and enhance energy metabolism by up-regulating the expression or activity of AMPK and sirtuins.
In light of the demonstrated cardioprotective effects of SGLT2 inhibitors (SGLT2i) in heart failure patients, these agents have been integrated into standard heart failure clinical guidelines, irrespective of the patient's diabetic status. Considering the well-established cardiotoxicity associated with anthracycline use, a thorough literature review was conducted to explore the potential of SGLT2i as adjunctive therapy to mitigate cardiac toxicity in breast cancer patients undergoing anthracycline-based chemotherapy. However, the search yielded only preclinical evidence, which highlighted the promising role of dapagliflozin. Consequently, this clinical trial aims to evaluate the efficacy of dapagliflozin as adjunctive therapy in breast cancer patients receiving anthracyclines, with a specific focus on preventing or delaying the onset of cardiotoxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dapagliflozin group who consist of at least 20 breast cancer patients who receive 4 cycles of anthracyclines ( each cycle every 21 days ) with dapagliflozin 10 mg tablet once daily.
Drug: Dapagliflozin 10mg Tab
Control group who consist of at least 20 breast cancer patients who receive 4 cycles of anthracyclines ( each cycle every 21 days ) only.
Dapagliflozin 10 mg tablet orally, once daily. Started 7 days before the first cycle of anthracyclines till the end of last anthracyclines dose. taken orally, once daily. Started from 5 to 7 days before the first cycle of anthracyclines till the end of last anthracycline dose.
Also known as: Dapablix 10 mg
N-terminal pro-B-type natriuretic peptide (NT-pro BNP) testing
Monitoring the serum at Baseline and after the last cycle of anthracyclines. Changes in serum NT-Pro BNP from baseline will be calculated and compared between groups
Time frame: Baseline and after the last cycle of anthracyclines ( 0 and 2 to 3 months from baseline)
Echocardiography by measuring left ventricular ejection fraction (LVEF)
LVEF (%) will be assessed using M-mode and 2D echocardiography performed by an experienced operator blinded to the patient's history. Changes in LVEF from baseline will be calculated and compared between groups at each time point.
Time frame: a) Baseline b) After the last cycle of anthracyclines (approximately 2 to 3 months from baseline) c) 3 months after the end of chemotherapy (approximately 5 to 6 months from baseline) d) As needed for any symptomatic patients
Plan to share: No
Started Sep 2024 (actual). Primary completion is estimated for Oct 2025, 13 months after the start.
Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 13 months is below that.
Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapagliflozin
Helwan University